COLL (Collegium Pharmaceutical) EPS (Basic) : $2.71 (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical EPS (Basic)?

Collegium Pharmaceutical's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $0.29. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $2.71.

Collegium Pharmaceutical's EPS (Diluted) for the three months ended in Sep. 2024 was $0.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $2.33.

Collegium Pharmaceutical's EPS without NRI for the three months ended in Sep. 2024 was $1.61. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was 6.24.

During the past 12 months, Collegium Pharmaceutical's average EPS without NRIGrowth Rate was 24.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 93.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Collegium Pharmaceutical's highest 3-Year average EPS without NRI Growth Rate was 93.10% per year. The lowest was -21.60% per year. And the median was 7.20% per year.

Collegium Pharmaceutical EPS (Basic) Historical Data

The historical data trend for Collegium Pharmaceutical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical EPS (Basic) Chart

Collegium Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.68

0.78

2.05

-0.74

1.43

Collegium Pharmaceutical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															0.61	0.96	0.86	0.60	0.29

Collegium Pharmaceutical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Collegium Pharmaceutical's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(48.155	-	0)	/	33.741
	=	1.43

Collegium Pharmaceutical's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(9.335	-	0)	/	32.259
	=	0.29

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.71

Collegium Pharmaceutical (NAS:COLL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Collegium Pharmaceutical EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Collegium Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

354:Germany

Address

100 Technology Center Drive, Stoughton, MA, USA, 02072

Website

https://www.collegiumpharma.com

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Executives

Thomas B Smith	officer: EVP and Chief Medical Officer	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Shirley R. Kuhlmann	officer: EVP and General Counsel	780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Tupper Colleen	officer: EVP & Chief Financial Officer	C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Scott Dreyer	officer: EVP & Chief Commercial Officer	780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Joseph Ciaffoni	director, officer: President and CEO	100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
John Gordon Freund	director	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Rita J. Balice-gordon	director	C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane	director	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Richard Malamut	officer: EVP and Chief Medical Officer	100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming	officer: Vice President, Product Devlp	780 DEDHAM STREET, SUITE 800, CANTON MA 02021